Testicular cancer laboratory findings

Jump to: navigation, search

Testicular cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Testicular cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Biopsy

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Testicular cancer laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Testicular cancer laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Testicular cancer laboratory findings

CDC on Testicular cancer laboratory findings

Testicular cancer laboratory findings in the news

Blogs on Testicular cancer laboratory findings

Directions to Hospitals Treating Testicular cancer

Risk calculators and risk factors for Testicular cancer laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gertrude Djouka, M.D.[2], Shanshan Cen, M.D. [3]

Overview

An elevated concentration of blood tumor marker tests is diagnostic of testicular cancer.

Laboratory Tests

Tumor marker tests:[1][2]

Tumor type Tumor markers
Human chorionic gonadotropin (HCG) Alpha-fetoprotein (AFP) Lactate dehydrogenase (LDH)
Seminoma -
Choriocarcinoma ↑↑ -
Yolk sac tumor -
Embryonal tumor
Teratoma -

Sex cord stromal testicular tumor

Leydig cell tumor[3]

Sertoli cell tumor[3]

References

  1. Milose JC, Filson CP, Weizer AZ, Hafez KS, Montgomery JS (December 2011). "Role of biochemical markers in testicular cancer: diagnosis, staging, and surveillance". Open Access J Urol. 4: 1–8. doi:10.2147/OAJU.S15063. PMC 3818947. PMID 24198649.
  2. Gilligan TD, Seidenfeld J, Basch EM, Einhorn LH, Fancher T, Smith DC, Stephenson AJ, Vaughn DJ, Cosby R, Hayes DF (July 2010). "American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors". J. Clin. Oncol. 28 (20): 3388–404. doi:10.1200/JCO.2009.26.4481. PMID 20530278.
  3. 3.0 3.1 Al-Agha OM, Axiotis CA (February 2007). "An in-depth look at Leydig cell tumor of the testis". Arch. Pathol. Lab. Med. 131 (2): 311–7. doi:10.1043/1543-2165(2007)131[311:AILALC]2.0.CO;2. PMID 17284120.

Linked-in.jpg